单个国家的数据不值得信任吧？国内也没用这个方法治疗

被限流！不知原因

“We believe we have a study that is highly generalizable to the current COVID environment in the U.S. and globally,” says Eiger CEO David Cory. He says that whereas the current leading antiviral, Pfizer’s Paxlovid, is given as a series of pills over 5 days,

a single shallow injection of interferon—similar to those people with type 1 diabetes routinely self-administer—“has the potential to be a one-and-done therapy, especially for high-risk patients.”

Based on the press release, the results are “quite impressive,” says Andreas Wack, an immunologist at the Francis Crick Institute, who has studied the role of lambda interferons in COVID-19. “I’m very hopeful that this may go somewhere.”

研发主体真是EIGR Eiger BioPharmaceuticals, Inc. Stock Price & Overview $5.96 -0.19 (-3.09%) 这么好的消息股价反倒下降！

Now, a strikingly positive result from a large trial of nonhospitalized, high-risk people in Brazil has revived hopes. In a study of more than 1900 people, those who received a single shot of a drug called peginterferon lambda within 7 days of developing symptoms of COVID-19 were

Interferon therapy shows striking results against COVID-19 Given early, one shot sliced hospitalization risk by half in large trial 一针但尽早使用！